News

17th March 2025

BerGenBio announces advancement of its strategic review

26th February 2025

BerGenBio Fourth Quarter Results 2024

25th February 2025

BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives

18th February 2025

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

7th January 2025

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

26th November 2024

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

20th November 2024

BerGenBio Appoints Olav Hellebø as CEO

13th November 2024

BerGenBio Third Quarter Results 2024

6th November 2024

BerGenBio ASA: Invitation to third quarter 2024 results webcast